

## Special Issue

# Advances and Applications of Regulatory Genomics in Multiple Myeloma

### Message from the Guest Editor

This Special Issue will mainly focus on the study and application of the several layers of genetic regulation that are fundamental for multiple myeloma development, progression, extramedullar disease, resistance and relapse. Potential topics include but are not limited to:

- Defining and characterising the myeloma and myeloma bone marrow's microenvironment epigenome and its changes during disease progression
- The correlation between genetic and epigenetic alterations to define myeloma subgroups
- The role of non-coding genome in myeloma development and progression
- The role of microRNA in myeloma development and progression
- The role of epigenetic regulation in myeloma plasticity
- Epi-drugs and their application in myeloma therapy
- Recent advances in epigenetic biomarkers for their use in diagnostics, patients' stratification and prognosis
- Use of epigenetic/gene-regulatory drugs for target resistance and relapse (pharmacological, immune or cellular therapy)
- Single-cell multi-omics approaches to define gene-regulatory networks

---

### Guest Editor

Dr. Valentina Caputo

Cancer, Infection and Therapeutics Research Group, School of Applied and Health Science, College of Health and Life Science, London South Bank University, London, UK

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/182772](https://mdpi.com/si/182772)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).